홈 > 시장보고서 > 의약품

시장보고서

상품코드

1482460

미세잔존질환 검사 시장 : 기술별, 용도별, 최종사용자별, 지역별

Minimal Residual Disease Testing Market, By Technology (Flow Cytometry, Polymerase chain reaction, and Next generation sequencing), By Application, By End User, By Geography

발행일: 2024년 04월 | 리서치사:

Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

미세잔존질환 검사 시장은 2024년 23억 1,000만 달러로 추정되며 2031년에는 49억 7,000만 달러에 달할 것으로 예상되며 2024년부터 2031년까지 11.6%의 CAGR을 기록할 것으로 예상됩니다.

보고서 범위		보고서 상세
기준 연도	2023	2024년 시장 규모	23억 1,000만 달러
실적 데이터	2019-2023년	예측 기간	2024-2031년
예측 기간 2024-2031년 CAGR:	11.60%	2031년 예측치	49억 7,000만 달러

그림. 미세잔존질환 검사 시장 점유율(%), 지역별, 2024년

Minimal Residual Disease Testing Market-IMG1

미세잔존질환(MRD) 검사는 1차 치료 후 체내에 남아있을 수 있는 미량의 암세포를 검출하는 검사로, 혈액 전문의와 종양 전문의가 치료 효과를 모니터링하고 환자의 예후를 예측하는 데 중요한 도구입니다. 보다 더 일찍 질병 재발 위험이 높은 환자를 식별할 수 있습니다. MRD를 민감하게 검출하기 위해 다중 파라미터 유세포 분석, 대립 유전자 특이적 올리고뉴클레오티드 정량 PCR, 차세대 염기서열 분석 등 여러 가지 기술이 사용되고 있습니다. 사용되고 있습니다. 다양한 유형의 혈액암에서 MRD 검사의 적용이 확대되고 기술이 향상됨에 따라 향후 몇 년 동안 시장이 크게 성장할 것으로 예상됩니다.

시장 역학:

세계 미세잔존질환 검사 시장은 혈액암 발병률 증가, 치료 모니터링에 MRD 검사 도입 증가, 의사들의 인식 증가에 힘입어 성장하고 있습니다. 그러나 숙련된 전문가 부족, 검사 방법의 고가화, 일부 지역에서의 상환 문제 등이 시장 성장을 저해하고 있습니다. 각 업체들이 민감도가 향상되고 자동화된 플랫폼을 갖춘 다양한 신제품을 출시하고 있으며, 이는 주요 비즈니스 기회로 작용하고 있습니다. 예를 들어, 개인 맞춤형 치료와 액체 생검 기술은 새로운 분야입니다. 기업과 연구기관의 공동 연구도 새로운 지역으로의 시장 확장을 촉진하고 있으며, COVID-19 팬데믹이 의료 자원에 미치는 영향은 도전 과제이지만, 현재 시나리오에서는 원격의료와 재택 검체 채취가 MRD 모니터링의 연속성을 지원하고 있습니다.

본 조사의 주요 특징

이 보고서는 2023년을 기준 연도로 하여 예측 기간(2024-2031년)의 시장 규모와 연평균 성장률(CAG%)을 통해 전 세계 미세잔존질환 검사 시장을 상세히 분석합니다.
다양한 부문의 잠재적 수익 성장 기회를 확인하고, 이 시장에 대한 매력적인 투자 제안 매트릭스를 설명합니다.
또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략 등에 대한 주요 인사이트도 제공합니다.
이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과 및 전략과 같은 매개 변수를 기반으로 세계 미세 잔존 병변 검사 시장의 주요 기업을 프로파일링합니다.
이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
세계 미세잔존질환 검사 시장은 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
이해관계자들은 세계 미세잔존질환 검사 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

기업 개요
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche Ltd
- Guardant Health, Inc.
- Adaptive Biotechnologies
- Invitae Corporation
- ASURAGEN, INC.
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- Natera, Inc.
- Sysmex Inostics, Inc.
- Amgen Inc.
- FOUNDATION MEDICINE, INC.
- Sebia
- Myriad Genetics, Inc.

제10장 애널리스트의 견해

애널리스트의 견해
Coherent Opportunity Map

제11장 참고문헌과 조사 방법

참고문헌
조사 방법

ksm 24.05.28

The minimal residual disease testing market is estimated to be valued at USD 2.31 Bn in 2024 and is expected to reach USD 4.97 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 11.6% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 2.31 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	11.60%	2031 Value Projection:	US$ 4.97 Bn

Figure. Minimal Residual Disease Testing Market Share (%), By Region 2024

Minimal Residual Disease (MRD) testing involves detecting tiny amounts of residual cancer cells that may remain in the body after initial treatment. It is an important tool for both hematologists and oncologists to monitor treatment response and predict outcomes for patients. MRD testing allows physicians to identify those who may be at higher risk of disease relapse earlier than other methods. This helps determine if additional therapies or closer monitoring is needed. Several technologies such as multiparameter flow cytometry, allele-specific oligonucleotide quantitative PCR, and next generation sequencing are used to detect MRD with high sensitivity. With growing applications of MRD testing across different types of blood cancers and improving technologies, the market is expected to witness significant growth in the coming years.

Market Dynamics:

The global minimal residual disease testing market is driven by rising incidence of hematological cancers, increasing adoption of MRD testing in treatment monitoring, and growing awareness among physicians. However, lack of skilled professionals, high index of testing methods, and reimbursement issues in some regions are restraining the market growth. Various new product launches by players with improved sensitivity and automated platforms present key opportunities. For instance, personalized therapy and liquid biopsy techniques are emerging areas. Collaborations between companies and research institutes are also supporting market expansion into new geographies. The effects of the COVID-19 pandemic on healthcare resources is a challenge, though telemedicine and home-based sample collection aid continuity of MRD monitoring in current scenario.

Key Features of the Study:

This report provides an in-depth analysis of the global minimal residual disease testing market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global minimal residual disease testing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study includes Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Adaptive Biotechnologies, Invitae Corporation, ASURAGEN, INC., Invivoscribe, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Sysmex Inostics, Inc., Amgen Inc., FOUNDATION MEDICINE, INC., Sebia, and Myriad Genetics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global minimal residual disease testing market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global minimal residual disease testing market

Detailed Segmentation-

Technology:
- Flow Cytometry
- Polymerase chain reaction (PCR)
- Next generation sequencing
Application:
- Lymphoma
- Solid Tumors
- Others
End User:
- Hospitals
- Clinics
- Research Laboratories
- Others
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Bio-Rad Laboratories, Inc.
- Hoffmann-La Roche Ltd
- Guardant Health, Inc.
- Adaptive Biotechnologies
- Invitae Corporation
- ASURAGEN, INC.
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- Natera, Inc.
- Sysmex Inostics, Inc.
- Amgen Inc.
- FOUNDATION MEDICINE, INC.
- Sebia
- Myriad Genetics, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Technology
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Epidemiology
Recent Developments
Acquisitions and Partnerships Scenario
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Minimal Residual Disease Testing Market- Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Minimal Residual Disease Testing Market, By Technology, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Flow Cytometry
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Polymerase chain reaction (PCR)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Minimal Residual Disease Testing Market, By Application, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Lymphoma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Solid Tumors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Minimal Residual Disease Testing Market, By End User, 2019 - 2031, (USD Bn)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospitals
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Research Laboratories
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Minimal Residual Disease Testing Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Regions, 2020-2031
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
  - Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
  - Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
  - Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
  - Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Technology, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Bio-Rad Laboratories, Inc.*
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- F. Hoffmann-La Roche Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Guardant Health, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Adaptive Biotechnologies
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Invitae Corporation
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- ASURAGEN, INC.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Invivoscribe, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Laboratory Corporation of America Holdings
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Natera, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sysmex Inostics, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- FOUNDATION MEDICINE, INC.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sebia
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Myriad Genetics, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies

10. Analyst View

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us and Sales Contact

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,500

￦ 6,511,000

PDF (Multi User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,000

￦ 10,128,000

PDF (Enterprise User License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,469,000

※ 부가세 별도

미세잔존질환 검사 시장 : 기술별, 용도별, 최종사용자별, 지역별

Minimal Residual Disease Testing Market, By Technology (Flow Cytometry, Polymerase chain reaction, and Next generation sequencing), By Application, By End User, By Geography

시장 역학:

본 조사의 주요 특징

목차

제1장 조사 목적과 가정

제2장 시장 전망

제3장 시장 역학, 규제, 동향 분석

제4장 세계의 미세잔존질환 검사 시장 : COVID-19 팬데믹의 영향

제5장 세계의 미세잔존질환 검사 시장 : 기술별, 2019-2031년

제6장 세계의 미세잔존질환 검사 시장 : 용도별, 2019-2031년

제7장 세계의 미세잔존질환 검사 시장 : 최종사용자별, 2019-2031년

제8장 세계의 미세잔존질환 검사 시장 : 지역별, 2019-2031년

제9장 경쟁 상황